CLINTON BYBEE
CIK 1219043 · last filed 2022-08-16
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$449.41M
Companies
16
Total Filings
39
Lifetime Open-Market Net
$60.75M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| VIR | 10%+ Owner | 208,852 | $8.85 | $1.85M | $0 | 2 | 2022-08-16 |
| BEAM | 10%+ Owner | 2,949,630 | $26.29 | $77.55M | $0 | 1 | 2021-07-02 |
| Karuna Therapeutics, Inc. (KRTX) Delisted | 10%+ Owner | 1,532,049 | $329.83 | $505.32M | $22.40M | 3 | 2021-01-12 |
| PI | Director | 17,125 | $133.03 | $2.28M | $97.7K | 14 | 2020-10-23 |
| Metacrine, Inc. (MTCR) Delisted | 10%+ Owner | 158,734 | $0.49 | $78.6K | $20.93M | 1 | 2020-09-22 |
| DNLI | 10%+ Owner | 10,668,749 | $24.05 | $256.58M | $0 | 1 | 2019-08-12 |
| Syros Pharmaceuticals, Inc. (SYRS) Delisted | 10%+ Owner | 430,205 | $0.00 | $172 | -$2.94M | 1 | 2019-07-17 |
| Unity Biotechnology, Inc. (UBX) Delisted | 10%+ Owner | 629,860 | $0.20 | $126.0K | $0 | 1 | 2018-05-07 |
| Sienna Biopharmaceuticals, Inc. (SNNA) Delisted | 10%+ Owner | 2,750,575 | — | — | $0 | 1 | 2017-08-01 |
| XTERA COMMUNICATIONS, INC. (XCOM) Delisted | Director | 1,885,090 | — | — | $7.50M | 5 | 2016-10-13 |
| VBI VACCINES INC. (VBIV) Delisted | 10%+ Owner | 134,928 | $0.07 | $8.8K | $0 | 1 | 2015-08-17 |
| PULM | 10%+ Owner | — | $1.68 | — | $0 | 1 | 2015-06-25 |
| Sage Therapeutics, Inc. (SAGE) Delisted | 10%+ Owner | 2,124,699 | $8.68 | $18.44M | $0 | 2 | 2015-06-22 |
| Bellerophon Therapeutics, Inc. (BLPH) Delisted | 10%+ Owner | 64,377 | $0.01 | $773 | $12.76M | 1 | 2015-02-23 |
| AGIO | 10%+ Owner | 3,088,590 | $35.99 | $111.16M | $0 | 2 | 2015-02-23 |
| Juno Therapeutics, Inc. (JUNO) Delisted | 10%+ Owner | 7,347,015 | — | — | $0 | 1 | 2014-12-23 |
Recent Filings · Page 2 of 4
39 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2019-08-30 | PI | Other (J) | −331,171 | $0 | EDGAR |
| 2019-08-15 | PI | Exer (M) | +4,754 | $0 | EDGAR |
| 2019-08-12 | DNLI | Other (J) | −2,000,000 | $0 | EDGAR |
| 2019-08-02 | PI | Other (J) | −321,562 | $0 | EDGAR |
| 2019-07-17 | Syros Pharmaceuticals, Inc. (SYRS) Delisted | Sell (S) | −378,000 | -$2.94M | EDGAR |
| 2019-07-02 | Karuna Therapeutics, Inc. (KRTX) Delisted | Mixed | +23,540,104 | $22.40M | EDGAR |
| 2019-05-07 | PI | Other (J) | −301,419 | $0 | EDGAR |
| 2018-08-16 | PI | Mixed | +2,023 | $0 | EDGAR |
| 2018-05-07 | Unity Biotechnology, Inc. (UBX) Delisted | Conv (C) | +70,060,438 | $0 | EDGAR |
| 2017-11-13 | PI | Buy (P) | +4,000 | $97.7K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.